Sign In
Buy ALT
$2.92
+0.0500 (+1.74%)
At Close: Jun 04, 2026
ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings
10:56am, Monday, 24'th Jun 2024
Altimmune (NASDAQ: ALT ) stock is one of the top trending tickers this morning, with shares up about 28% as of this writing. This surge comes after the company released results from a 48-week study of
Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALT
05:15am, Monday, 24'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 24, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follo
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune Lawsuit - ALT
05:15am, Monday, 24'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 24, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follo
IMMINENT ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit!
05:00am, Monday, 24'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 24, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc.
Altimmune stock price is still at risk despite Pemvidutide hopes
04:36am, Monday, 24'th Jun 2024
Altimmune (NASDAQ: ALT) stock price drifted upwards on Monday amid optimism that it will become a leading player in the weight loss industry. It rose by over 2%, meaning that it has soared by over 25%
Full analysis of body composition data showed class-leading lean mass preservation with 21.9% of weight loss attributable to lean mass and 78.1% attributable to fat Full analysis of body composition d
NEW YORK, NY / ACCESSWIRE / June 23, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follo
Shareholders that lost money on Altimmune, Inc.(ALT) should contact Levi & Korsinsky about pending Class Action - ALT
10:19am, Sunday, 23'rd Jun 2024
NEW YORK, NY / ACCESSWIRE / June 23, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follo
NEW YORK, June 23, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April
NEW YORK, NY / ACCESSWIRE / June 23, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follo
UPCOMING ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit!
05:00am, Sunday, 23'rd Jun 2024
NEW YORK, NY / ACCESSWIRE / June 23, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc.
Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
06:03pm, Saturday, 22'nd Jun 2024
NEW YORK, NY / ACCESSWIRE / June 22, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follo
NEW YORK, NY / ACCESSWIRE / June 22, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follo
Pemvidutide elicited significant weight loss and decreases in pro-inflammatory serum lipids associated with atherogenesis and cardiovascular disease risk Pemvidutide elicited significant weight loss a
NEW YORK, June 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) and certain
